Literature DB >> 26119014

Bone Metastasis-Related MicroRNAs: New Targets for Treatment?

Qian Zhao, Fengming Luo, Junrong Ma, Xijie Yu1.   

Abstract

MicroRNAs (miRNAs) are a new class of small noncoding RNAs of 19-25 nucleotides that function as negative posttranscriptional gene regulators. MiRNAs hybridize to the 3' untranslated region (UTR) of target mRNAs and repress translation or mediate mRNA cleavage. MiRNAs critically regulate tumorigenesis and progression by targeting oncogenes, tumor suppressor genes, or genes related to proliferation, angiogenesis, and apoptosis. Different tumor types and tumors at different stages exhibit unique miRNA profiles. MiRNAs show promise as potential biomarkers for cancer diagnostics, progression, and response to treatment. The role of miRNAs in promoting bone metastases is under investigated. We summarize recent findings on the mechanisms by which miRNAs may regulate bone metastatic spread of breast cancer, prostate cancer, lung cancer and multiple myeloma. We review similarities and differences in miRNA profiles that may explain the variety of molecular pathways underling metastatic spread to the skeleton in different cancers. Finally, we discuss the exciting potential of using miRNAs as diagnostics and therapeutic targets to reduce the risk of bone metastases in cancer, from the perspective of data provided by recent pre-clinical and clinical studies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26119014     DOI: 10.2174/1568009615666150629102408

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  5 in total

Review 1.  Nanoparticle-based targeted cancer strategies for non-invasive prostate cancer intervention.

Authors:  Nicholas H Farina; Areg Zingiryan; Michael A Vrolijk; Scott D Perrapato; Steven Ades; Gary S Stein; Jane B Lian; Christopher C Landry
Journal:  J Cell Physiol       Date:  2018-04-16       Impact factor: 6.384

Review 2.  Targeting the Metastatic Bone Microenvironment by MicroRNAs.

Authors:  Marie-Therese Haider; Hanna Taipaleenmäki
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-27       Impact factor: 5.555

Review 3.  The potential function of microRNAs as biomarkers and therapeutic targets in multiple myeloma.

Authors:  Bingying Zhu; Shaoqing Ju; Haidan Chu; Xianjuan Shen; Yan Zhang; Xi Luo; Hui Cong
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

4.  miR‑144‑3p inhibits the proliferation, migration and angiogenesis of multiple myeloma cells by targeting myocyte enhancer factor 2A.

Authors:  Fei Tian; Huihan Wang; Huanxin Ma; Yuan Zhong; Aijun Liao
Journal:  Int J Mol Med       Date:  2020-07-06       Impact factor: 4.101

5.  microRNA Prognostic Signature for Postoperative Success of Metastatic Orthopedic Cancers: Implications for Precision Microsurgery.

Authors:  Shi-Bao Xu; Rong-Hao Fan; Xiao Qin; Rui-Ming Han
Journal:  Front Cell Dev Biol       Date:  2021-07-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.